Advertisement

Examples of Novel Registered Prophylactic Vaccines, HPV, and JEV

  • Katrin Dubischar-Kastner
  • Michelle Vichnin
  • Carlos Sattler
Chapter

Abstract

Clinical development programs for vaccines can differ drastically in terms of required studies and number of study participants. Immunological correlates of protection allow down-sizing a development program substantially, since immunogenicity endpoints may be used instead of efficacy endpoints. The success of a vaccine will largely depend on its uptake in medical practice. Recommendations for the use of a vaccine are often made by expert advisory groups which are independent from the approving agency. These panels might review further factors for their decision to recommend a vaccine, such as burden of disease, feasibility of implementation, and cost-effectiveness of immunization on a population level. The present chapter presents an overview of two contrasting clinical development programs and recommendations for use for two recently registered vaccines: the Japanese Encephalitis vaccine IXIARO, a travelers’ vaccine which was licensed based on immunogenicity criteria (neutralizing antibodies), and the Human Papillomavirus Vaccine Gardasil, licensed based on efficacy in preventing precancerous lesions.

Keywords

Cervical Intraepithelial Neoplasia Japanese Encephalitis Virus Genital Wart Japanese Encephalitis Vaccine Adverse Event Reporting System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM (2009) Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 27:7270–7281PubMedCrossRefGoogle Scholar
  2. American Cancer Society (2011) Anal cancer. What is anal cancer? http://www.cancer.org/Cancer/AnalCancer/DetailedGuide/anal-cancer-what-is-key-statistics. Updated June 20, 2011. Accessed 17 Jul 2011
  3. American Cancer Society (2011) Penile cancer. What is penile cancer? http://www.cancer.org/Cancer/PenileCancer/DetailedGuide/penile-cancer-key-statistics. Updated June 21, 2011. Accessed 17 Jul 2011
  4. Andersen MM, Rønne T (1991) Side-effects with Japanese encephalitis vaccine. Lancet 337:1044PubMedCrossRefGoogle Scholar
  5. Arbyn M, Raifu AO, Autier P, Ferlay J (2007) Burden of cervical cancer in Europe: estimates for 2007. Ann Oncol 18:1708–1715PubMedCrossRefGoogle Scholar
  6. Ault KA, Future II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369:1861–1868PubMedCrossRefGoogle Scholar
  7. Australian Government Department of Health and Ageing (2007) National Immunisation Program Schedule (Valid From 1 July 2007). http://www.health.gov.au/internet/immunise/publishing.nsf/content/E875BA5436C6DF9BCA2575BD001C80BF/$File/nip-schedule-card-july07.pdf. Accessed 12 Aug 2009
  8. Australian Government Department of Health and Ageing, National Health and Medical Research Council (2008) Chapter 3.10: Japanese encephalitis. In: The Australian Immunisation Handbook, 9th Edn. Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home Last accessed 13 Sep 2011
  9. Australian Government Department of Health and Ageing. Human Papillomavirus (HPV) (2011) www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. Updated April 4, 2011. Accessed 8 Jul 2011
  10. Backes DM, Kurman RJ, Pimenta JM, Smith JS (2009) Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 20(4):449–457PubMedCrossRefGoogle Scholar
  11. Barr E, Sings HL (2008) Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 26:6244–6257PubMedCrossRefGoogle Scholar
  12. Barr E, Tamms G (2007) Quadrivalent HPV vaccine. Clin Infect Dis 45:609–617PubMedCrossRefGoogle Scholar
  13. Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16–S24PubMedCrossRefGoogle Scholar
  14. Bauer H, Wright G, Chow J (2011) Evidence of HPV vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2009. Presented at: ISSTDR 2011; July 10–13, 2011; Quebec City, Canada. Abstract 01-S02.04Google Scholar
  15. Beasley DWC, Lewthwaite P, Solomon T (2008) Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 10(8):95–106CrossRefGoogle Scholar
  16. Berg SW, Mitchell BS et al (1997) Systemic reactions in US marine corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 24(2):265–266PubMedCrossRefGoogle Scholar
  17. Bernard JE, Butler MO, Sandweiss L, Weidner N (2008) Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol 16(3):215–220PubMedCrossRefGoogle Scholar
  18. Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM et al (2001) Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358:791–5PubMedCrossRefGoogle Scholar
  19. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD et al (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118(5):2135–2145PubMedCrossRefGoogle Scholar
  20. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A et al (2009) Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 29(2):95–101Google Scholar
  21. Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K et al (2010) A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 28:4719–4730PubMedCrossRefGoogle Scholar
  22. Bonnez W (2002) Papillomavirus. Clin Virol:557–596Google Scholar
  23. Boyce W, Doherty M, Fortin C, MacKinnon D (2003) Canadian youth, sexual health, and HIV/AIDS study. Council of Ministers of Education, CanadaGoogle Scholar
  24. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K et al (2008) Interim estimates of human papillomavirus vaccination coverage in a school-based program in Australia. Commun Dis Intell 32:457–461PubMedGoogle Scholar
  25. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 337:2085–2092CrossRefGoogle Scholar
  26. Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M et al (2011) The humoral response to GARDASIL® over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 7:230–238PubMedCrossRefGoogle Scholar
  27. Bryan JT (2007) Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 25:3001–3006PubMedCrossRefGoogle Scholar
  28. Bryan JT, Taddeo F, Skulsky D, Jansen KU, Frain BM, Qadadri B et al (2006) Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas. J Med Virol 78(1):117–124PubMedCrossRefGoogle Scholar
  29. Cai B, Ronnett BM, Stoler M, Ferenczy A, Kurman RJ, Sadow D et al (2007) Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists. Am J Surg Pathol 31(12):1854–1860PubMedCrossRefGoogle Scholar
  30. Cain JM, Howett MK (2000) Preventing cervical cancer. Science 288:1753–1754PubMedCrossRefGoogle Scholar
  31. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315PubMedCrossRefGoogle Scholar
  32. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K et al (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 105:28–37PubMedCrossRefGoogle Scholar
  33. Centers for Disease Control and Prevention (1993) Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 42(No. RR-1):1–15Google Scholar
  34. Centers for Disease Control and Prevention (2004) Surveillance summaries: youth risk behavior surveillance—United States, 2003. MMWR Surveill Summ 53(2):1–96Google Scholar
  35. Centers for Disease Control and Prevention (2009) HPV-associated vaginal cancer rates by race and ethnicity. http://www.cdc.gov/cancer/hpv/statistics/vaginal.htm. Updated June 22, 2009. Accessed 12 August 2011
  36. Centers for Disease Control and Prevention (2010a) National, state and local area vaccination coverage among adolescents aged 13–17 years–United States, 2009. MMWR Morb Mortal Wkly Rep 59(32):1018–1023Google Scholar
  37. Centers for Disease Control and Prevention (2010b) Japanese encephalitis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 59(1):1–21Google Scholar
  38. Centers for Disease Control and Prevention (2011) Sexually transmitted diseases. HPV Vaccine Monitoring. http://www.cdc.gov/std/hpv/monitoring-rpt.htm. Updated June 2011. Accessed 5 Aug 2011
  39. Centers for Disease Control and Prevention (CDC) (2011) Update on Japanese encephalitis vaccine for children – United States. MMWR Morb Mortal Rep Wkly 60(20):664–665Google Scholar
  40. Christensen ND, Höpfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA et al (1994) Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75:2271–2276PubMedCrossRefGoogle Scholar
  41. Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15:6758–6762PubMedCrossRefGoogle Scholar
  42. Clarke P, Ebel C, Catotti DN, Stewart S (1996) The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 7:197–200PubMedCrossRefGoogle Scholar
  43. Cornelison TL (2000) Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Curr Opin Oncol 12:466–473PubMedCrossRefGoogle Scholar
  44. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S et al (2009) Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114(6):1170–1177PubMedCrossRefGoogle Scholar
  45. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124:1626–1636PubMedCrossRefGoogle Scholar
  46. DeFraites RF, Gambel JM, Hoke CH, Sanchez JL, Withers BG, Karabatsos N et al (1999) Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 61:288–93PubMedGoogle Scholar
  47. Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG). Hinweise und Empfehlungen zu Reiseimpfungen. April 2011. Available at: http://www.dtg.org/uploads/media/Impfungen2011.pdf Last accessed on 22 Sept 2011
  48. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W et al (2005) Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 12(8):959–969PubMedGoogle Scholar
  49. Dodge JA, Eltabbakh GH, Mount SL, Walker RP, Morgan A (2001) Clinical features and risk recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 83:363–369PubMedCrossRefGoogle Scholar
  50. Donne AJ, Clarke R (2010) Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. Int J STD AIDS 21:381–385PubMedCrossRefGoogle Scholar
  51. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H et al (2011) Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11(1):39–44PubMedCrossRefGoogle Scholar
  52. Dubischar-Kastner K, Eder S et al. (2010) Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51. Vaccine 28;5197–5202Google Scholar
  53. Eder S, Dubischar-Kastner K et al (2011) Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO(R), IC51. Vaccine 29:2607–2612PubMedCrossRefGoogle Scholar
  54. EMA (2006) Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/164653/2005Google Scholar
  55. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS (2009) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85:499–502PubMedCrossRefGoogle Scholar
  56. FDA (2008) Guidance for industry: General principles for the development of vaccines to protect against global infectious diseases, September 2008. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm078379.pdf last accessed 23 Sept 2011
  57. Ferris D; for the Protocol 018 Investigators (2011) First look at effectiveness data from a long-term extension study of Gardasil in adolescents. Presented at: EUROGIN 2011. 8–11 May 2011; Lisbon, Portugal. Abstract SS 9–1Google Scholar
  58. Fleischer AB Jr, Parrish CA, Glenn R, Feldman SR (2001) Condylomata acuminata (genital warts)—patient demographics and treating physicians. Sex Transm Dis 28:643–647PubMedCrossRefGoogle Scholar
  59. FUTURE II Study Group (2007) Quadrivalent HPV vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927CrossRefGoogle Scholar
  60. Future, II Study Group (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 340(c3493):1–9Google Scholar
  61. Garland SM, M Hernandez-Avila, Wheeler CM, Perez G, Harper DM, Leodolter S, for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRefGoogle Scholar
  62. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, for the Quadrivalent Human Papillomavirus Vaccine Phase III Investigators et al (2009a) Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114:1179–1188PubMedCrossRefGoogle Scholar
  63. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R et al (2009b) Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:805–814PubMedCrossRefGoogle Scholar
  64. Georgitis JW, Fasano MB (2001) Allergenic components of vaccines and avoidance of vaccine-related adverse events. Curr Allergy Rep 1:11–17PubMedCrossRefGoogle Scholar
  65. Gillison ML, Shah KV (2001) Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13:183–188PubMedCrossRefGoogle Scholar
  66. Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D et al (2007) Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196:1153–1162PubMedCrossRefGoogle Scholar
  67. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364:401–411PubMedCrossRefGoogle Scholar
  68. Global Advisory Committee on Vaccine Safety (2005) 9–10 June 2005. Wkly Epidemiol Rec. 80(28):241–8.Google Scholar
  69. Greaves WL, Orenstein WA, Hinman AR, Nersesian WS (1983) Clinical efficacy of rubella vaccine. Ped Infect Dis 2(4):284–286CrossRefGoogle Scholar
  70. Haga T, Kim S-H, Jensen RH, Darragh T, Palefsky JM (2001) Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 26:256–262PubMedCrossRefGoogle Scholar
  71. Hagensee ME, Yaegashi N, Galloway D (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315–322PubMedGoogle Scholar
  72. Halstead SB, Jacobsen J (2008) Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit P (eds) Vaccines, 5th edn. Saunders, Philadelphia, PA, pp 311–352Google Scholar
  73. Hammon W, Sather GE (1973) Passive immunity for arbovirus infection. 1. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am J Trop Med 22:524–34Google Scholar
  74. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–35PubMedCrossRefGoogle Scholar
  75. Health Protection Agency (2004) Focus on prevention: HIV and other sexually transmitted infections in the United Kingdom in 2003—an update: November 2004. London, England, United KingdomGoogle Scholar
  76. Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL et al (1996) Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case–control study. Lancet 347:1583–6PubMedCrossRefGoogle Scholar
  77. Hills S, Griggs A, Fisher M (2010) Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am J Trop Med Hyg 82(5):930–936PubMedCrossRefGoogle Scholar
  78. Hippeläinen M, Syrjänen S, Hippeläinen M, Koskela H, Pulkkinen J, Saarikoski S et al (1993) Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 20(6):321–328PubMedCrossRefGoogle Scholar
  79. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL et al (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319:608–14PubMedCrossRefGoogle Scholar
  80. Hombach J, Solomon T et al (2005) Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23(45):5205–5211PubMedCrossRefGoogle Scholar
  81. Hoots BE, Palefsky JM, Pimenta JM, Smith JS (2009) Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124(10):2375–2383PubMedCrossRefGoogle Scholar
  82. Insinga RP, Dasbach EJ, Myers ER (2003) The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36:1397–1403PubMedCrossRefGoogle Scholar
  83. Insinga RP, Glass AG, Rush BB (2004) Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 191(1):105–13PubMedCrossRefGoogle Scholar
  84. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, for the FUTURE I Investigators, et al (2011) Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 20:287–296PubMedCrossRefGoogle Scholar
  85. IXIARO Japanese encephalitis vaccine (inactivated, adsorbed) (2010) Summary of product characteristics. Accesible at the EMA homepage: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000963/human_med_000862.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d124
  86. Jansen KU, Shaw AR (2004) Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 55:319–331PubMedCrossRefGoogle Scholar
  87. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ et al (1995) Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13(16):1509–1514PubMedCrossRefGoogle Scholar
  88. JE-VAX®, Japanese encephalitis virus vaccine inactivated (1997) Prescribing Information. Aventis Pasteur Inc., USA. FebruaryGoogle Scholar
  89. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 101:281–288PubMedCrossRefGoogle Scholar
  90. Jones RW (2001) Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaec Oncol 22(6):393–402Google Scholar
  91. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693–1702PubMedCrossRefGoogle Scholar
  92. Kaltenbock A, Dubischar-Kastner K, Eder G et al (2009) Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27:4483–9PubMedCrossRefGoogle Scholar
  93. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS (2010) Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28:834–9PubMedCrossRefGoogle Scholar
  94. Kastenos S, Becker HD (2011) Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol 4:162–171CrossRefGoogle Scholar
  95. Kirbauer R, Booy F, Chang N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180–12184CrossRefGoogle Scholar
  96. Kjaer SK; for the HPV Vaccine Nordic Follow-Up Team (2011) An evaluation of the long-term effectivenss, immunogenicity, and safety of GARDASILTM in previously vaccinated women. Presented at: EUROGIN 2011. 8–11 May 2011; Lisbon, Portugal. Abstract PS 2–6Google Scholar
  97. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2:868–878CrossRefGoogle Scholar
  98. Koshiol JE, Laurent SA, Pimenta JM (2004) Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 31:748–752PubMedCrossRefGoogle Scholar
  99. Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102(5A):3–8PubMedCrossRefGoogle Scholar
  100. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475PubMedCrossRefGoogle Scholar
  101. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M et al (2010) Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol 162:1269–1277PubMedCrossRefGoogle Scholar
  102. Kurman RJ, Norris HJ, Wilkinson E (1992) Tumors of the cervix, vagina and vulva (3rd series, fascicle 4). In: Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington DC, pp 44–55Google Scholar
  103. Lacey CJ, Lowndes CM, Shah KV (2006) Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24:S35–S41CrossRefGoogle Scholar
  104. Langley PC, White DJ, Drake SM (2004) The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 15:501–508PubMedCrossRefGoogle Scholar
  105. Litle VR, Leavenworth JD, Darragh TM, Kosinski LA, Moore DH 2nd, Smith-McCune KK et al (2000) Angiogenesis, proliferation, and apoptosis in anal high-grade squamous intraepithelial lesions. Dis Colon Rectum 43(3):346–352PubMedCrossRefGoogle Scholar
  106. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ et al (1997) Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176:1141–1145PubMedCrossRefGoogle Scholar
  107. Lyons A, Kanesa-thasan N et al. (2007) A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25:3445–3453Google Scholar
  108. Lyons A, Kanesa-thasan N, Kuschner RA et al (2007) A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25:3445–3453PubMedCrossRefGoogle Scholar
  109. Mackenzie JS, Williams DT, Smith DW (2008) Japanese encephalitis virus: the geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas. Perspect Med Virol 16:201–268CrossRefGoogle Scholar
  110. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18–27PubMedCrossRefGoogle Scholar
  111. Markoff L (2000) Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18(Suppl 2):26–32PubMedCrossRefGoogle Scholar
  112. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, for the Centers for Disease Control and Prevention (CDC); for the Advisory Committee on Immunization Practices (ACIP) (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(2):1–24PubMedGoogle Scholar
  113. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF (2010) Post-licensure monitoring of HPV vaccine in the United States. Vaccine 28(30):4731–4737PubMedCrossRefGoogle Scholar
  114. Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, Burke DS et al (1989) Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 70:2037–49PubMedCrossRefGoogle Scholar
  115. Mathur A, Arora KL, Chaturvedi UC (1983) Host defense mechanisms against Japanese encephalitis virus infection in mice. J Gen Virol 64:805–11PubMedCrossRefGoogle Scholar
  116. Maw RD, Reitano M, Roy M (1998) An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 9:571–578PubMedCrossRefGoogle Scholar
  117. Mehanna H, Jones TM, Gregoire V, Ang KK (2010) Oropharyngeal carcinoma related to human papillomavirus. BMJ 340:c1439PubMedCrossRefGoogle Scholar
  118. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S (2009) Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 62:870–878PubMedCrossRefGoogle Scholar
  119. Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H et al (2011) Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin 7:768–775PubMedCrossRefGoogle Scholar
  120. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527PubMedCrossRefGoogle Scholar
  121. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjosé S, Hammouda D et al (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278–285PubMedCrossRefGoogle Scholar
  122. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K et al (2009) Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 373:1921–1922CrossRefGoogle Scholar
  123. Myers ER (2008) The economic impact of HPV vaccines: not just cervical cancer. Am J Obstet Gynecol 198:487–488PubMedCrossRefGoogle Scholar
  124. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB (2005) Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case–control study. Lancet 366:1375–78PubMedCrossRefGoogle Scholar
  125. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C et al (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25:4931–4939PubMedCrossRefGoogle Scholar
  126. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N et al (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10:108–115PubMedGoogle Scholar
  127. Oya A, Kurane I (2007) Japanese Encephalitis for a Reference to International Travelers. J Trav Med 14(4):259–268Google Scholar
  128. Pagliusi SR, Aguado TA (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:569–578PubMedCrossRefGoogle Scholar
  129. Palefsky JM (2007) HPV infection in men. Dis Markers 23:261–272PubMedGoogle Scholar
  130. Palefsky JM (2010) Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health 46:S12–S19PubMedCrossRefGoogle Scholar
  131. Palefsky JM, Giuliano AR, Goldstone S et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576–1585PubMedCrossRefGoogle Scholar
  132. Parida M, Dash PK et al (2006) Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 12(9):1427–1430PubMedCrossRefGoogle Scholar
  133. Plesner AM, Arlien-Soborg P, Herning M (1998) Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol 5(5):479–485PubMedCrossRefGoogle Scholar
  134. Plotkin S (2008) Correlates of vaccine-induced immunity. Clin Infect Dis 47:401–9PubMedCrossRefGoogle Scholar
  135. Plotkin SA, Reef S (2004) Rubella vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccine, 4th edn. Saunders, Philadelphia, PA, pp 707–743Google Scholar
  136. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, The VAERS Team et al (2002) Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 110:71CrossRefGoogle Scholar
  137. Public Health Agency of Canada (2007) Statement on human papillomavirus vaccine. Canada Communicable Disease Report, 15 February, 2007. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-02/index-eng.php. Updated February 20, 2007. Accessed 7 Aug 2011
  138. Public Health Agency of Canada (2010) http://www.phac-aspc.gc.ca/std-mts/hpv-vph/fact-faits-vacc-eng.php. Updated 19 April 2010. Accessed 15 Aug 2011
  139. Ragin CCR, Modugno F, Gollin SM (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104–114PubMedCrossRefGoogle Scholar
  140. Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, for the Protocol 025 Investigators et al (2010) Safety, tolerability, and immunogenicity of GARDASIL given concomitantly with Menactra and Adacel. Pediatrics 125:1142–1151PubMedCrossRefGoogle Scholar
  141. Robinson HC, Russell ML, Csokonay WM (1991) Japanese encephalitis vaccine and adverse effects among travelers. Can Dis Wkly Rep 17(32):173–7PubMedGoogle Scholar
  142. Rose RC, Bonnez W, Reichman RC, Garcea RL (1993) Expression of HPV type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J Virol 67(4):1936–1944PubMedGoogle Scholar
  143. Ruff TA, Eisen D, Fuller A, Kass R (1991) Adverse reactions to Japanese encephalitis vaccine. Lancet 338:881–2PubMedCrossRefGoogle Scholar
  144. Ryan DP, Compton CC, Mayer RJ (2000) Carcinoma of the anal canal. N Engl J Med 342(11):792–800PubMedCrossRefGoogle Scholar
  145. Saah A; for the HPV Vaccine Nordic Follow-Up Team (2011) A registry-based long-term follow-up study of the safety of the quadrivalent HPV (qHPV) vaccine in Scandinavia. Presented at: EUROGIN 2011. 8–11 May 2011; Lisbon, Portugal. Abstract SS 9–12Google Scholar
  146. Sakaguchi M, Inouye S (2000) IgE sensitization to gelatin: the probable role of gelatin containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine 18:2055–58PubMedCrossRefGoogle Scholar
  147. Salisbury D, Ramsey M, Noakes K (Eds) (2006) Chapter 20: Japanese encephalitis. In: Immunisation against infectious disease, The Stationary Office. Third Edition (updated 7 November 2011). Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_117991.pdf. Last accessed 31 January 2012
  148. Sanchez JL, Hoke CH, McCown J, DeFraites RF, Takafuji ET, Diniega BM et al (1990) Further experience with Japanese encephalitis vaccine. Lancet 335:972–3PubMedCrossRefGoogle Scholar
  149. de Sanjosé S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, for the Retrospective International Survey and HPV Time Trends Study Group et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–1056PubMedCrossRefGoogle Scholar
  150. Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20:207–225PubMedCrossRefGoogle Scholar
  151. Saraiya M, Hariri S (2011) HPV vaccine effect: is the glass half full or empty? Lancet 337:2057–2058CrossRefGoogle Scholar
  152. Schiffman M, Solomon D (2003) Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 127(8):946–949PubMedGoogle Scholar
  153. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907PubMedCrossRefGoogle Scholar
  154. Schiller JT, Day PM, Kines RC (2010) Current understanding of the mechanism of HPV infection. Gynecol Oncol 118:S12–S17PubMedCrossRefGoogle Scholar
  155. Scholefield JH, Ogunbiyi OA, Smith JHF, Rogers K, Sharp F (1994) Treatment of anal intraepithelial neoplasia. Br J Surg 81:1238–1240PubMedCrossRefGoogle Scholar
  156. Scholefield JH, Castle MT, Watson NFS (2005) Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 92:1133–1136PubMedCrossRefGoogle Scholar
  157. Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A et al (2008) Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 26(34):4382–4386PubMedCrossRefGoogle Scholar
  158. Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E (2009) Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15):2188–2193PubMedCrossRefGoogle Scholar
  159. Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z (2011) Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine 29:8669–8676PubMedCrossRefGoogle Scholar
  160. Sénécal M, Brisson M, Maunsell E, Ferenczy A, Franco EL, Ratnam S et al (2011) Loss of quality of life associated with genital warts—baseline analyses from a prospective study. Sex Transm Infect 87:209–215PubMedCrossRefGoogle Scholar
  161. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A et al (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus. JAMA 302(7):750–757PubMedCrossRefGoogle Scholar
  162. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632PubMedCrossRefGoogle Scholar
  163. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM (2009) Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 113:917–924PubMedGoogle Scholar
  164. Sobhani I, Walker F, Roudot-Thoraval F, Abramowitz L, Johanet H, Hénin D et al (2004) Anal carcinoma: incidence and effect of cumulative infections. AIDS 18(11):1561–1569PubMedCrossRefGoogle Scholar
  165. Solomon T (2006) Control of Japanese encephalitis-within our grasp? N Engl J Med 355(9):869–71PubMedCrossRefGoogle Scholar
  166. Srivastava AK, Putnak JR et al (2001) A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19(31):4557–4565PubMedCrossRefGoogle Scholar
  167. Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E (2007) Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 29:155–162PubMedCrossRefGoogle Scholar
  168. Ständige Impfkommission Am Robert Koch Institut (2011) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2011; Epidemiologisches Bull (30):275–294. Available at: http://www.rki.de/cln_109/nn_1493664/DE/Content/Infekt/EpidBull/Archiv/2011/30__11,templateId=raw,property=publicationFile.pdf/30_11.pdf Last Accessed Sept 13,2011
  169. Stanley M (2010) Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117:S5–S10PubMedCrossRefGoogle Scholar
  170. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA et al (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553–11557PubMedCrossRefGoogle Scholar
  171. Tauber E, Kollaritsch H et al (2007) Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370(9602):1847–1853PubMedCrossRefGoogle Scholar
  172. Tauber E, Kollaritsch H et al (2008) Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 198(4):493–499PubMedCrossRefGoogle Scholar
  173. Tepper M, Schofield S, Committee to Advise on Tropical Medicine and Travel (CATMAT) (2011) Statement on protection against Japanese encephalitis. Can Commun Dis Rep 37(1):1–13Google Scholar
  174. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T (2011) Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29:4544–4555PubMedCrossRefGoogle Scholar
  175. Tsai TF (2000) New Initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine 18(Suppl 2):1–25PubMedCrossRefGoogle Scholar
  176. Van den Hurk A, Ritchie SA, Mackenzie JS (2009) Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54:17–35PubMedCrossRefGoogle Scholar
  177. Van Gessel Y, Klade C, Putnak R, Formica A, Krasaesub S, Spruth M, Cena B, Tungtaeng A, Gettayacamin M, Dewasthaly S (2011) Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. Vaccine 29(35):5925–593PubMedCrossRefGoogle Scholar
  178. Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D et al (2010) An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 29(4):314–318PubMedGoogle Scholar
  179. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278PubMedCrossRefGoogle Scholar
  180. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer A, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRefGoogle Scholar
  181. Watson AJM, Smith BB, Whitehead MR, Sykes PH, Frizelle FA (2006) Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 76:715–717PubMedCrossRefGoogle Scholar
  182. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH et al (2001) Sexual behaviour in Britain: early heterosexual experience. Lancet 358:1843–1850PubMedCrossRefGoogle Scholar
  183. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E (2008) Protocol 11 Study Investigators. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26:686–696PubMedCrossRefGoogle Scholar
  184. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB et al (2002) External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 35(Suppl 2):S210–S224PubMedCrossRefGoogle Scholar
  185. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157(3):218–226PubMedCrossRefGoogle Scholar
  186. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA (2005) Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191:731–738PubMedCrossRefGoogle Scholar
  187. Wong AK, Chan RC, Aggarwal N, Singh MK, Nichols WS, Bose S (2009) Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol 143:1–7Google Scholar
  188. World Health Organization (2007) Human papillomaviruses. In: IARC Monographs on the evaluation of carcinogenic risks to humans, vol 90. International Agency for Research on Cancer, Lyon, FranceGoogle Scholar
  189. World Health Organization (2009) WHO papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 84(15):118–131Google Scholar
  190. World Health Organization. GLOBOCAN 2008. Australia. Most frequent cancers: men. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=36. Accessed 20 July 2011
  191. World Health Organization. GLOBOCAN 2008. Canada. Most frequent cancers: men. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=124. Accessed 20 Jul 2011
  192. World Health Organization. GLOBOCAN 2008. Cervical cancer incidence and mortality worldwide in 2008 summary. http://globocan.iarc.fr/factsheets/cancers/cervix.asp. Accessed 8 Jul 2011
  193. Zacharisen MC, Conley SF (2006) Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseases. Pediatrics 118:1925–1931PubMedCrossRefGoogle Scholar
  194. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251–257PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Katrin Dubischar-Kastner
    • 1
  • Michelle Vichnin
    • 2
  • Carlos Sattler
    • 2
  1. 1.Intercell AGViennaAustria
  2. 2.Merck VaccinesWhitehouse StationUSA

Personalised recommendations